相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
Ibrahim Yakoub-Agha et al.
HAEMATOLOGICA (2020)
Determinants of response and resistance to CAR T cell therapy
Stefanie Lesch et al.
SEMINARS IN CANCER BIOLOGY (2020)
Cytokine release syndrome in severe COVID-19
John B. Moore et al.
SCIENCE (2020)
Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma
Paolo Strati et al.
BLOOD ADVANCES (2020)
Inhibition of IL1β by Canakinumab May Be Effective against Diverse Molecular Subtypes of Lung Cancer: An Exploratory Analysis of the CANTOS Trial
Connie C. Wong et al.
CANCER RESEARCH (2020)
Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies
Elizabeth L. Siegler et al.
FRONTIERS IN IMMUNOLOGY (2020)
Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
Gils Roex et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Cytokine Storm
David C. Fajgenbaum et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity
Alberto Mantovani et al.
IMMUNITY (2019)
CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia
Jing Pan et al.
LEUKEMIA (2019)
MCC950 blocks enhanced interleukin-1β production in patients with NLRP3 low penetrance variants
E. Schuh et al.
CLINICAL IMMUNOLOGY (2019)
IL-1 Family Members in Cancer; Two Sides to Every Story
Kevin J. Baker et al.
FRONTIERS IN IMMUNOLOGY (2019)
IL-1R3 blockade broadly attenuates the functions of six members of the IL-1 family, revealing their contribution to models of disease
Jesper Falkesgaard Hojen et al.
NATURE IMMUNOLOGY (2019)
GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts
Rosalie M. Sterner et al.
BLOOD (2019)
Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation
Irena Kaplanov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Critical Care Management of Chimeric Antigen Receptor T Cell-related Toxicity Be Aware and Prepared
Elie Azoulay et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2019)
In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy
Jorge Garcia Borrega et al.
HEMASPHERE (2019)
The NLRP3 inflammasome: molecular activation and regulation to therapeutics
Karen V. Swanson et al.
NATURE REVIEWS IMMUNOLOGY (2019)
IL-1 and IL-1 regulatory pathways in cancer progression and therapy
Alberto Mantovani et al.
IMMUNOLOGICAL REVIEWS (2018)
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
Sattva S. Neelapu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study
Jurgen Sota et al.
CLINICAL RHEUMATOLOGY (2018)
Interleukin-1 blockade in cardiovascular diseases: a clinical update
Leo F. Buckley et al.
EUROPEAN HEART JOURNAL (2018)
Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes
Mona M. Hosseini et al.
LEUKEMIA (2018)
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
Margherita Norelli et al.
NATURE MEDICINE (2018)
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Theodoros Giavridis et al.
NATURE MEDICINE (2018)
OLT1177, a ß-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation
Carlo Marchetti et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
CAR T cell immunotherapy for human cancer
Carl H. June et al.
SCIENCE (2018)
Interleukin 6-Mediated Endothelial Barrier Disturbances Can Be Attenuated by Blockade of the IL6 Receptor Expressed in Brain Microvascular Endothelial Cells
Kinga G. Blecharz-Lang et al.
TRANSLATIONAL STROKE RESEARCH (2018)
Cytokine release syndrome
Alexander Shimabukuro-Vornhagen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema
Matthew Torre et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2018)
IL-1β inflammatory response driven by primary breast cancer prevents metastasis-initiating cell colonization
Zafira Castano et al.
NATURE CELL BIOLOGY (2018)
Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy
Kevin A. Hay
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Cerebral autoinflammatory disease treated with anakinra
Yoonhyuk Jang et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2018)
Insights into the genomic landscape of MYD88 wild-type Waldenstrom macroglobulinemia
Zachary R. Hunter et al.
BLOOD ADVANCES (2018)
Therapeutic Approaches Targeting Inflammation in Cardiovascular Disorders
Daniel P. Jones et al.
BIOLOGY-BASEL (2018)
A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Farhad Ravandi et al.
BLOOD (2018)
The DNA Methylcytosine Dioxygenase Tet2 Sustains Immunosuppressive Function of Tumor-Infiltrating Myeloid Cells to Promote Melanoma Progression
Wen Pan et al.
IMMUNITY (2017)
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
Paul M. Ridker et al.
LANCET (2017)
MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study
Tamas Hickish et al.
LANCET ONCOLOGY (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
P. M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology
Rudragouda Channappanavar et al.
SEMINARS IN IMMUNOPATHOLOGY (2017)
Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
Juliane Gust et al.
CANCER DISCOVERY (2017)
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy
Kevin A. Hay et al.
BLOOD (2017)
Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myeloma
John A. Lust et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
MGUS to myeloma: a mysterious gammopathy of underexplored significance
Madhav V. Dhodapkar
BLOOD (2016)
Toxicities of chimeric antigen receptor T cells: recognition and management
Jennifer N. Brudno et al.
BLOOD (2016)
Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes
Torbjorn Kullenberg et al.
RHEUMATOLOGY (2016)
Proteolytic Processing of Interleukin-1 Family Cytokines: Variations on a Common Theme
Inna S. Afonina et al.
IMMUNITY (2015)
Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer
David S. Hong et al.
INVESTIGATIONAL NEW DRUGS (2015)
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
James N. Kochenderfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee et al.
LANCET (2015)
Blocking IL1β Pathway Following Paclitaxel Chemotherapy Slightly Inhibits Primary Tumor Growth but Promotes Spontaneous Metastasis
Tali Voloshin et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Targeting IRAK1 in T-Cell acute lymphoblastic leukemia
Charles Dussiau et al.
ONCOTARGET (2015)
The road to cure in multiple myeloma starts with smoldering disease
Karma Z. Salem et al.
EXPERT OPINION ON ORPHAN DRUGS (2015)
NLRP3 inflammasome and its inhibitors: a review
Bo-Zong Shao et al.
FRONTIERS IN PHARMACOLOGY (2015)
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee et al.
BLOOD (2014)
Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies
Shannon L. Maude et al.
CANCER JOURNAL (2014)
Beyond Tumor Necrosis Factor Inhibition: The Expanding Pipeline of Biologic Therapies for Inflammatory Diseases and Their Associated Infectious Sequelae
S. A. Novosad et al.
CLINICAL INFECTIOUS DISEASES (2014)
MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study
David S. Hong et al.
LANCET ONCOLOGY (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Marco L. Davila et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
IRAK1: oncotarget in MDS and AML
Levi J. Beverly et al.
ONCOTARGET (2014)
Targeting IRAK1 as a Therapeutic Approach for Myelodysplastic Syndrome
Garrett W. Rhyasen et al.
CANCER CELL (2013)
The Interleukin-1 Family: Back to the Future
Cecilia Garlanda et al.
IMMUNITY (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
James N. Kochenderfer et al.
BLOOD (2012)
From Myeloma Precursor Disease to Multiple Myeloma: New Diagnostic Concepts and Opportunities for Early Intervention
Ola Landgren et al.
CLINICAL CANCER RESEARCH (2011)
Understanding the mechanism of IL-1β secretion
Gloria Lopez-Castejon et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2011)
Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study
James Galea et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2011)
Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry
J. D. Greenberg et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Why not treat human cancer with interleukin-1 blockade?
Charles A. Dinarello
CANCER AND METASTASIS REVIEWS (2010)
IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function
Moshe Elkabets et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
Multiple Myeloma Precursor Disease
Ola Landgren et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
The serum and cerebrospinal fluid pharmacokinetics of anakinra after intravenous administration to non-human primates
Elizabeth Fox et al.
JOURNAL OF NEUROIMMUNOLOGY (2010)
Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1β-Induced Interleukin 6 Production and the Myeloma Proliferative Component
John A. Lust et al.
MAYO CLINIC PROCEEDINGS (2009)
Interleukin-1β-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors
Yakov Krelin et al.
CANCER RESEARCH (2007)
Interleukin-1β and signaling of interleukin-1 in vascular wail and circulating cells modulates the extent of neointima formation in mice
J Chamberlain et al.
AMERICAN JOURNAL OF PATHOLOGY (2006)
The paradox of pro-inflammatory cytokines in cancer
Charles A. Dinarello
CANCER AND METASTASIS REVIEWS (2006)
Polymorphisms of the interleukin-1β gene are associated with increased risk of non-small cell lung cancer
S Zienolddiny et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice
K Isoda et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
IL-1 is required for tumor invasiveness and angiogenesis
E Voronov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
A polymorphism of the interleukin-1β gene influences survival in pancreatic cancer
MD Barber et al.
BRITISH JOURNAL OF CANCER (2000)
Interleukin-1 polymorphisms associated with increased risk of gastric cancer
EM El-Omar et al.
NATURE (2000)
分享论文
